Trial to Evaluate Diarrhoea Discontinuations at 3 Cycles in Patients With Early-stage HER2+, HR+ Breast Cancer Treated With Neratinib Plus Loperamide Versus Neratinib Dose Escalation Plus Loperamide Administered as Needed Versus Neratinib Plus Loperamide Plus Colesevelam (DIANER)

Conditions:   Early-stage Breast Cancer;   HER2 Positive Breast Cancer;   Hormone Receptor Positive Interventions:   Drug: Neratinib;   Drug: Loperamide;   Drug: Colesevelam Sponsors:   Spanish Breast Cancer Research Group;   Puma Biotechnology, Inc.;   Pierre Fabre Laboratories Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials